51 results about "Heme oxygenase" patented technology

The invention provides a transgenic animal carrying two transgenes, one encoding a human decay accelerating factor (hDAF) and the other encoding a human heme oxygenase-1 (hHO)-1, which are useful for providing cells, tissues or organs therefrom for xenotransplantation.

Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble CD44 antigen, Angiopoietin-1, soluble Angiopoietin-1 receptor, C-X-C chemokine motif 5, soluble Endoglin, soluble Tumor-associated calcium signal transducer 1, Erythropoietin, soluble Fractalkine, Heme oxygenase 1, soluble Interleukin-1 receptor type II, soluble Interleukin-6 receptor subunit-alpha, Lymphotactin, Lymphotoxin-alpha, Stromelysin-1, C-C motif chemokine 22, C-C motif chemokine 5, and Thrombospondin-1 as diagnostic and prognostic biomarkers in renal injuries.

The invention provides a nanogel drug carrier for targeted delivery and consumption of a large amount of H2O2 and release of CO at the same time, and a preparation method and application thereof. Thenanogel drug carrier is a dendritic polypeptide nanogel drug carrier. The drug carrier comprises dendritic polypeptide nanogel as a carrier, and a carbon monoxide release molecules CORM401 loaded in an internal cavity of the dendritic polypeptide nanogel, and also comprises hyaluronic acid which is modified by folic acid and coats the surface of the dendritic polypeptide nanogel. A multifunctionalanti-inflammatory drug (CPHs) is prepared on the basis of the nanogel drug carrier disclosed by the invention. The drug carrier can enter activated macrophages in a HA-FA targeting manner, and rapidly release a large amount of CO is by consuming excessive H2O2. The generated CO not only can effectively inhibit cell proliferation, but also can obviously inhibit secretion of inflammatory factors byinducing activation (HO-1) of heme oxygenase and down-regulating expression of p38MAPK, NF-kB (p50 / p65) and TLR-2. The CPHs can consume a large amount of ROS at the osteoarthritis joint part, and effectively inhibit degradation of articular cartilage and extracellular matrix.

Inhibitors of microbial heme oxygenase and their use for treatment of microbial infections and bioremediation. The inhibitors of microbial heme oxygenase are useful against a new class of antimicrobial agents to target infections that are persistently difficult to combat with the current spectrum of antimicrobial agents. Screening methods for selecting inhibitors of microbial heme oxygenase.